Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma

Journal of Pediatric Surgery

Volumn 47, Issue 6, 2012, Pages 1267-1271

  Lautz, Timothy B ^a,b   Naiditch, Jessica A ^a,b   Clark, Sandra ^b   Chu, Fei ^b,c   Madonna, Mary Beth ^a,b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Chemotherapy resistance; Histone deacetylase inhibitor; Neuroblastoma; Vorinostat

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CAMBINOL; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CALORIMETRY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; WILD TYPE; XENOGRAFT;

EID: 84862500666     PISSN: 00223468     EISSN: 15315037     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2012.03.039     Document Type: Conference Paper

References (19)

1. De Bernardi B, Gerrard M, Boni L, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009;27:1034-40.
2. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009;27:1007-13.
3. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007;26:5310-8. (Pubitemid 47255917)
4. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51. (Pubitemid 43054973)
5. Duong V, Bret C, Altucci L, et al. Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res 2008;6: 1908-19.
6. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99. (Pubitemid 37361445)
7. Palmieri D, Lockman PR, Thomas FC, et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 2009;15:6148-57.
8. United States National Institute of Health: Clinical Trials. Available at: http://clinicaltrials.gov/ct2/results?term=neuroblastoma+and+vorinostat Accessed July 28th, 2011.
9. Coffey DC, Kutko MC, Glick RD, et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 2001;61:3591-4. (Pubitemid 32694967)
10. Fouladi M, Park JR, Stewart CF, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 2010;28:3623-9.
11. Ozaki K, Kishikawa F, Tanaka M, et al. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci 2008;99:376-84. (Pubitemid 351228495)
12. Heltweg B, Gatbonton T, Schuler AD, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006;66:4368-77.
13. Chu F, Chou PM, Zheng X, et al. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 2005;65:10183-7. (Pubitemid 41743708)
14. Rebbaa A, Chou PM, Mirkin BL. Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Mol Med 2001;7:393-400. (Pubitemid 33701974)
15. Witt O, Deubzer HE, Lodrini M, et al. Targeting histone deacetylases in neuroblastoma. Curr Pharm Des 2009;15:436-47.
16. Huang JM, Sheard MA, Ji L, et al. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. Mol Cancer Ther 2010;9:3289-301.
17. Muhlethaler-Mottet A, Flahaut M, Bourloud KB, et al. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. BMC Cancer 2006;6:214.
18. Mueller S, Yang X, Sottero TL, et al. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett 2011;306:223-9.
19. London WB, Castel V, Monclair T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol 2011;29:3286-92.